Purification and characterization of Eugeniin as an anti-herpesvirus compound from Geum japonicum and Syzygium aromaticum

Journal of Pharmacology and Experimental Therapeutics

Volumn 284, Issue 2, 1998, Pages 728-735

  Kurokawa, Masahiko ^a   Hozumi, Toyoharu ^b   Basnet, Purusotam ^a   Nakano, Michio ^a   Kadota, Shigetoshi ^a   Namba, Tuneo ^a   Kawana, Takashi ^c   Shiraki, Kimiyasu ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b Ctrl R and D Laboratory   (Japan)

^c UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; DNA POLYMERASE; EUGENIIN; PHOSPHONOACETIC ACID; THYMIDINE KINASE; THYMIDINE TRIPHOSPHATE; UNCLASSIFIED DRUG; VIRUS DNA;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DNA SYNTHESIS INHIBITION; DRUG ISOLATION; DRUG MECHANISM; DRUG PURIFICATION; ENZYME INHIBITION; HERPES SIMPLEX VIRUS 1; NONHUMAN; PLANT; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; VIRUS INHIBITION;

GEUM JAPONICUM; SYZYGIUM AROMATICUM;

EID: 0031884139     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Allaudeen HS (1985) Distinctive properties of DNA polymerases induced by herpes simplex virus type-1 and Epstein-Barr virus. Antiviral Res 5:1-12.
2. Birch CJ, Tachedjian G, Doherty RR, Hayes K and Gust ID (1990) Altered sensitivity to antiviral drugs of herpes simplex virus isolates from a patient with the acquired immunodeficiency syndrome. J Infect Dis 162:731-734.
3. Carr A and Cooper DA (1996) Current clinical experience with nevirapine for HIV infection. Adv Exp Med Biol 394:299-304.
4. Coen DM (1994) Acyclovir-resistant, pathogenic herpesviruses. Trends Microbiol 2:481-485.
5. Coen DM, Furman PA, Geleo PT and Schaffer PA (1982) Mutations in the herpes simplex virus DNA polymerase gene can donfer resistance to 9-β-D-arabinofurano-syladenine. J Virol 41:909-918.
6. De Clercq E, Descamps J, Verhelst G, Walker RT, Jones AS, Torrence PF and Shugar D (1980) Comparative efficacy of antiherpes drugs against different strains of herpes simplex virus. J Infect Dis 141:563-574.
7. Dixon M and Webb EC (1979) Enzyme inhibition and activation, in Enzymes (Dixon M, Webb EC, Thorne CJR and Tipton KF eds), 3rd ed., pp 332-467, Longman Group Ltd., London.
8. Dubbs DR and Kit S (1964) Mutant strains of herpes simplex virus deficient in thymidine kinase-inducing activity. Virology 22:493-502.
9. Dunkle LM, Arvin AM, Whitley RJ, Rotbart HA, Feder HM Jr, Feldman S, Gershon AA, Levy ML, Hayden GF, McGuirt PV, Harris J and Balfour HH Jr (1991) A controlled trial of acyclovir for chickenpox in normal children. N Engl J Med 325:1539-1544.
10. Elion GB, Furman PA, Fyfe JA, De Miranda P, Beauchamp L and Schaeffer HJ (1977) Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl)guanine. Proc Natl Acad Sci USA 12:5716-5720.
11. Erlich KS, Mills J, Chatis P, Mertz GJ, Busch DF, Follansbee SE, Grant RM and Crumpacker CS (1989) Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. N Engl J Med 320:293-296.
12. Fiddian AP, Brigden D, Yeo JM and Hickmott EA (1984) Acyclovir: An update of the clinical applications of this antiherpes agent. Antiviral Res 4:99-117.
13. Frank KB, Chiou J-F and Cheng Y-C (1985) Interaction of DNA polymerase and nucleotide analog triphosphates. Adv Enzyme Regul 24:377-384.
14. Fukuchi K, Sakagami H, Okuda T, Hatano T, Tanuma S, Kitajima K, Inoue Y, Inoue S, Ichikawa S, Nonoyama M and Konno K (1989) Inhibition of herpes simplex virus infection by tannins and related compounds. Antiviral Res 11:285-298.
15. Grob PM, Cao YZ, Munchmore E, Ho DD, Norris S, Pav JW, Shih CK and Adams J (1997) Prophylaxis agent HIV-1 infection in chimpanzees by nevirapine, a non-nucleoside inhibitor of reverse transcriptase. Nature Med 3:665-670.
16. Hammer SM (1997) Advances in antiretroviral therapy and viral load monitoring. AIDS 10:suppl, 3, S1-S11.
17. Honess RW and Roizman B (1973) Proteins specified by herpes simplex virus. XI. Identification and relative molar rates of synthesis of structural and nonstructural herpes virus polypeptides in the infected cell. J Virol 12:1347-1365.
18. Honess RW and Watson DH (1977) Herpes simplex virus resistance and sensitivity to phosphonoacetic acid. J Virol 21:584-600.
19. 1 tannins and related compounds as selective cytotoxic agents. J Nat Prod 55:1033-1043.
20. Kilby JM and Saag MS (1996) Clinical experience with non-nucleoside reverse transcriptase inhibitors: L-697,661 and nevirapine. Adv Exp Med Biol 394:291-298.
21. Kopp EB, Miglietta JJ, Shrutkowski AG, Shih C-K, Grob PM and Skoog MT (1991) Steady state kinetics and inhibition of HIV-1 reverse transcriptase by a nonnucleoside dipyridodiazepinone, BT-RG-587, using a heteropolymeric template. Nucleic Acid Res 19:3035-3039.
22. Kurokawa M, Hase K, Xu H-X, Yamamura J, Koyasu M, Satoh H, Kadota S, Hozumi T, Namba T and Shiraki K (1993a) A novel procedure for the identification of a fraction with anti-herpes simplex virus type 1 activity in vivo from hot-water extract of traditional medicines, Geum Japonicum Thunb. J Med Pharm Soc WAKAN-YAKU 10:195-203.
23. Kurokawa M, Nagasaka K, Hirabayashi T, Uyama S, Sato H, Kageyama T, Kadota S, Ohyama H, Hozumi T, Namba T and Shiraki K (1995a) Efficacy of traditional herb medicines in combination with acyclovir against herpes simplex virus type 1 infection in vitro and in vivo. Antiviral Res 27:19-37.
24. Kurokawa M, Nakano M, Ohyama H, Hozumi T, Namba T and Shiraki K (1997) Prophylactic efficacy of traditional herbal medicines against recurrent harpes simplex virus type 1 infection from latently infected ganglia in mice. J Dermatol Sci 14:76-84.
25. Kurokawa M, Ochiai H, Nagasaka K, Neki M, Xu H, Kadota S, Sutardjo S, Matsumoto T, Namba T and Shiraki K (1993b) Antiviral traditional medicines against herpes simplex virus (HSV-1), poliovirus, and measles virus in vitro and their therapeutic efficacies for HSV-1 infection in mice. Antiviral Res 22:175-188.
26. Kurokawa M, Ochiai H, Nakajima K and Niwayama S (1990) Inhibitory effect of protein kinase C inhibitor on the replication of influenza type A virus. J Gen Virol 71:2149-2155.
27. Kurokawa M, Sato H, Ohyama H, Hozumi T, Namba T, Kawana T and Shiraki K (1995b) Effects of traditional herb medicines against herpes simplex virus (HSV) type 2 and acyclovir-resistant HSV type 1 in vitro and in vivo. J Tradit Med 12:187-194.
28. Larder BA, Derse D, Cheng Y-C and Darby G (1983) Properties of purified enzymes induced by pathogenic drug-resistant mutants of herpes simplex virus. J Biol Chem 258:2027-2033.
29. Lee S-H, Tanaka T, Nonaka G and Nishioka I (1990) Hydrolysable tannins from Euphorbia thymifolia. Phytochemistry 29:3621-3625.
30. Merta A, Votruba I, Rosenberg I, Otmar M, Hrebabecky H, Bernaerts R and Holy A (1990) Inhibition of herpes simplex virus DNA polymerase by diphosphates of acyclic phosphonylmethoxyalkyl nucleotide analogues. Antiviral Res 13:209-218.
31. Meyers JD, Wade JC, Mitchell CD, Saral R, Lietman PS, Durack DT, Levin MJ, Segreti AC and Balfour HH (1982) Multicenter collaborative trial of intravenous acyclovir for treatment of mucocutaneous herpes simplex virus infection in the immunocompromised host. Am J Med 73:229-235.
32. Nakane H, Baizarini J, De Cercq E and Ono K (1988) Differential inhibition of various deoxyribonucleic acid polymerases by Evans blue and aurintricarboxylic acid. Eur J Biochem 177:91-96.
33. Nishiyama Y, Suzuki M, Yamauchi M, Maeno K and Yoshida S (1984) Characterization of an aphidicolin-resistant mutant of herpes simplex virus type 2 which induces an altered viral DNA polymerase. Virology 135:87-96.
34. Nonaka G, Harada M and Nishioka I (1980) Eugeniin, a new ellagitannin from cloves. Chem Pharm Bull 28:685-687.
35. Norris SA, Kessler HA and Fife KH (1988) Severe progressive herpetic whitlow caused by an acyclovir-resistant virus in a patient with AIDS. J Infect Dis 157: 209-210.
36. Nugier F, Colin JN, Aymard M and Langlois M (1992) Occurrence and characterization of acyclovir-resistant herpes simplex virus isolates: Report on a two-year sensitivity screening survey. J Med Virol 36:1-12.
37. Oliver NM, Collins P, Van der Meer J and Van't Wout JW (1989) Biological and biochemical characterization of clinical isolates of herpes simplex virus type 2 resistant to acyclovir. Antimicrob Agents Chemother 33:635-640.
38. Ono K (1987) Discrimination of cellular and viral DNA polymerases in retrovirus-induced cells: Principle and applications. Bull Inst Pasteur 85:3-35.
39. Ostrander M and Cheng Y-C (1980) Properties of herpes simplex virus type 1 and type 2 DNA polymerase. Biochim Biophys Acta 609:232-245.
40. Pelosi E, Hicks KA, Sacks SL and Coen DM (1992) Heterogeneity of a herpes simplex virus clinical isolate exhibiting resistance to acyclovir and foscarnet. Adv Exp Med Biol 312:151-158.
41. Powell KL and Purifoy DJ (1977) Nonstructural proteins of herpes simplex virus: I. Purification of the induced DNA polymerase. J Virol 24:618-626.
42. Reusser P, Cordonnier C, Einsele H, Engelhard D, Link H, Locasciulli A, Ljungman P for the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation (EBMT) (1996) European survey of herpesvirus resistance to antiviral drugs in bone marrow transplant recipients. Bone Marrow Transplant 17:813-817.
43. Romero DL, Busso M, Tan C-K, Reusser F, Palmer JR, Poppe SM, Aristoff PA, Downey KM, So AG, Resnick L and Tarpley WG (1991) Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication. Proc Natl Acad Sci USA 88:8806-8810.
44. Seidlin M and Straus SE (1984) Treatment of mucocutaneous herpes simplex infections. Clin Dermatol 2:100-116.
45. Sibrack CD, Gutman LT, Wilfert CM, McLaren C, St. Clair MH, Keller PM and Barry DW (1982) Pathogenicity of acyclovir-resistant herpes simplex virus type 1 from an immunodeficient child. J Infect Dis 146:673-682.
46. Smerdon SJ, Jäger J, Wang J, Kohlstaedt LA, Chirino AJ, Friedman JM, Rice PA and Steitz TA (1994) Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 91:3911-3915.
47. Takechi M and Tanaka Y (1981) Purification and characterization of antiviral substance from the bud of Syzygium aromatica. Planta Med 42:69-74.
48. Whitley RJ, Alford CA, Hirsch MS, Schooley RT. Luby JP, Aoki FY, Hanley D, Nahmoas AJ and Soong S-J (1986) Vidarabine versus acyclovir therapy in herpes simplex encephalitis. N Engl J Med 314:144-149.
49. Whitley RJ, Arvin A, Prober C, Burchett S, Corey L, Powell D, Plotkin S, Starr S, Alford C, Connor J, Jacobs R, Nahmias A, Soong S-J and the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group (1991) A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. N Engl J Med 324:444-449.
50. Yoshida S, Kondo T and Ando T (1974) Multiple molecular species of cytoplasmic DNA polymerase from calf thymus. Biochim Biophys Acta 353:463-474.